Contact

All Stories

  1. The barriers to interprofessional care for cancer cachexia among Japanese healthcare providers: A nationwide survey

    Article • Journal of Cachexia Sarcopenia and Muscle, November 2023, Wiley

    MD. PhD. Tateaki Naito

  2. Impact of Early Chemotherapy Resumption on the Outcome after Staphylococcus aureus Bacteremia in Patients with Solid Tumors: A Retrospective Study in a Single Tertiary Cancer Center in Japan

    Article • European Journal of Cancer Care, September 2023, Hindawi Publishing Corporation

    MD. PhD. Tateaki Naito

  3. Efficacy and safety of carboplatin and etoposide in older extensive‐stage small‐cell lung cancer patients with a poor performance status

    Article • Thoracic Cancer, January 2023, Wiley

    MD. PhD. Tateaki Naito

  4. Efficacy and safety of anamorelin in patients with cancer cachexia: Post‐hoc subgroup analyses of a placebo‐controlled study

    Article • Cancer Medicine, November 2022, Wiley

    MD. PhD. Tateaki Naito

  5. Pharmacotherapy for Advanced Non-Small Cell Lung Cancer with Performance Status 2 without Druggable Gene Alterations: Could Immune Checkpoint Inhibitors Be a Game Changer?

    Article • Cancers, October 2022, MDPI AG

    Satoshi Ikeda, MD. PhD. Tateaki Naito

  6. Pharmacotherapy for Advanced Non-Small Cell Lung Cancer with Performance Status 2 without Druggable Gene Alterations: Could Immune Checkpoint Inhibitors be a Game Changer?

    Article • September 2022, MDPI AG

    Satoshi Ikeda, MD. PhD. Tateaki Naito

  7. Exploring the educational needs for severe immune-related adverse events of PD-1/PD-L1 inhibitors in advanced lung cancer: A single-center observational study

    Article • Asia-Pacific Journal of Oncology Nursing, August 2022, Elsevier

    MD. PhD. Tateaki Naito

  8. Clinical impact of tumour burden on the efficacy of PD‐1/PD‐L1 inhibitors plus chemotherapy in non‐small‐cell lung cancer

    Article • Cancer Medicine, July 2022, Wiley

    MD. PhD. Tateaki Naito

  9. Prospective evaluation of the relationship between response and exposure of total and unbound erlotinib in non-small cell lung cancer patients

    Article • Cancer Chemotherapy and Pharmacology, July 2022, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  10. O15-1 Responder analysis of anamorelin in patients with cancer cachexia

    Article • Annals of Oncology, July 2022, Elsevier

    MD. PhD. Tateaki Naito

  11. EL08 Supportive care in cancer

    Article • Annals of Oncology, July 2022, Elsevier

    MD. PhD. Tateaki Naito

  12. MO44-5 The clinical outcome of patients with oligometastatic non-small cell lung cancer treated with first-line immunotherapy

    Article • Annals of Oncology, July 2022, Elsevier

    MD. PhD. Tateaki Naito

  13. Predicting the efficacy of first‐line immunotherapy by combining cancer cachexia and tumor burden in advanced non‐small cell lung cancer

    Article • Thoracic Cancer, June 2022, Wiley

    MD. PhD. Tateaki Naito

  14. Impact of losing adipose tissue on outcomes from PD‐1/PD‐L1 inhibitor monotherapy in non‐small cell lung cancer

    Article • Thoracic Cancer, April 2022, Wiley

    MD. PhD. Tateaki Naito

  15. A multicenter, open‐label, single‐arm study of anamorelin (ONO‐7643) in patients with cancer cachexia and low body mass index

    Article • Cancer, February 2022, Wiley

    MD. PhD. Tateaki Naito

  16. Phase 1b study of ramucirumab in combination with irinotecan plus cisplatin in chemo-naïve patients with extensive-stage small-cell lung cancer

    Article • Lung Cancer, February 2022, Elsevier

    MD. PhD. Tateaki Naito

  17. Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study

    Article • BMC Cancer, November 2021, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  18. Correction to: Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non‑small cell lung cancer

    Article • Investigational New Drugs, November 2021, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  19. Long-term survival data of patients with limited disease small cell lung cancer: a retrospective analysis

    Article • Investigational New Drugs, October 2021, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  20. Long-term outcomes in extensive disease small cell lung cancer patients treated without immune checkpoint inhibitors

    Article • Japanese Journal of Clinical Oncology, October 2021, Oxford University Press (OUP)

    MD. PhD. Tateaki Naito

  21. Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer

    Article • Investigational New Drugs, October 2021, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  22. Impact of angiogenesis inhibitor eligibility on the prognosis of patients with non‐small cell lung cancer harboring EGFR mutation

    Article • Cancer Medicine, September 2021, Wiley

    MD. PhD. Tateaki Naito

  23. Impact of weight loss on treatment with PD-1/PD-L1 inhibitors plus chemotherapy in advanced non-small-cell lung cancer

    Article • Supportive Care in Cancer, September 2021, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  24. Trophoblast cell-surface antigen 2 expression in lung cancer patients and the effects of anti-cancer treatments

    Article • Journal of Cancer Research and Clinical Oncology, September 2021, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  25. Challenges in enhancing physical performance in thoracic cancer cachexia

    Article • Thoracic Cancer, September 2021, Wiley

    MD. PhD. Tateaki Naito

  26. Barriers in Nursing Practice in Cancer Cachexia: A Scoping Review

    Article • Asia-Pacific Journal of Oncology Nursing, September 2021, Elsevier

    MD. PhD. Tateaki Naito

  27. 1249P Pharmacokinetic and dose finding study of osimertinib in patients with impaired renal function and low body weight

    Article • Annals of Oncology, September 2021, Elsevier

    MD. PhD. Tateaki Naito

  28. 1651P Phase I study of ramucirumab in combination with irinotecan plus cisplatin in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC)

    Article • Annals of Oncology, September 2021, Elsevier

    MD. PhD. Tateaki Naito

  29. Rechallenge with previously administered epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer with leptomeningeal metastasis

    Article • Investigational New Drugs, July 2021, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  30. MO21-1 Prognostic value of pneumonitis after durvalumab in locally-advanced non-small cell lung cancer

    Article • Annals of Oncology, July 2021, Elsevier

    MD. PhD. Tateaki Naito

  31. Impact of Cancer Cachexia on Treatment With PD-1/PD-L1 Inhibitors Plus Chemotherapy in Advanced Non-small-Cell Lung Cancer

    Article • June 2021, Research Square

    MD. PhD. Tateaki Naito

  32. Impact of Physical Inactivity on the Risk of Disability and Hospitalization in Older Patients with Advanced Lung Cancer

    Article • Journal of Multidisciplinary Healthcare, June 2021, Taylor & Francis

    MD. PhD. Tateaki Naito

  33. Comparison of clinical features between immune-related sclerosing cholangitis and hepatitis

    Article • Investigational New Drugs, May 2021, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  34. Impact of prior ALK-tyrosine kinase inhibitor on pemetrexed-based chemotherapy in patients with advanced ALK positive non-small cell lung cancer.

    Article • Journal of Clinical Oncology, May 2021, American Society of Clinical Oncology (ASCO)

    MD. PhD. Tateaki Naito

  35. Chemoradiotherapy for limited-stage small-cell lung cancer and interstitial lung abnormalities

    Article • Radiation Oncology, March 2021, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  36. Development of home-based resistance training for older patients with advanced cancer: The exercise component of the nutrition and exercise treatment for advanced cancer program

    Article • Journal of Geriatric Oncology, March 2021, Elsevier

    MD. PhD. Tateaki Naito

  37. Pseudo-Meigs’s syndrome

    Article • BMJ Case Reports, February 2021, BMJ

    MD. PhD. Tateaki Naito

  38. Detection of programmed cell death-ligand 1 using 22C3 antibody in patients with unresectable stage III non-small cell lung cancer receiving chemoradiotherapy

    Article • International Journal of Clinical Oncology, January 2021, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  39. Clinical impact of walking capacity on the risk of disability and hospitalizations among elderly patients with advanced lung cancer

    Article • Supportive Care in Cancer, January 2021, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  40. Days Spent at Home near the End of Life in Japanese Elderly Patients with Lung Cancer: Post hoc Analysis of a Prospective Study

    Article • Asia-Pacific Journal of Oncology Nursing, January 2021, Medknow

    MD. PhD. Tateaki Naito

  41. Efficacy of pembrolizumab in patients with brain metastasis caused by previously untreated non-small cell lung cancer with high tumor PD-L1 expression

    Article • Lung Cancer, January 2021, Elsevier

    MD. PhD. Tateaki Naito

  42. Nursing Management of Cancer Cachexia: A New Frontier

    Article • Asia-Pacific Journal of Oncology Nursing, January 2021, Medknow

    MD. PhD. Tateaki Naito

  43. Unfavorable impact of decreased muscle quality on the efficacy of immunotherapy for advanced non‐small cell lung cancer

    Article • Cancer Medicine, December 2020, Wiley

    MD. PhD. Tateaki Naito

  44. Proposing synchronous oligometastatic non–small‐cell lung cancer based on progression after first‐line systemic therapy

    Article • Cancer Science, November 2020, Wiley

    MD. PhD. Tateaki Naito

  45. Retrospective analysis of osimertinib re-challenge after osimertinib-induced interstitial lung disease in patients with EGFR-mutant non-small cell lung carcinoma

    Article • Investigational New Drugs, September 2020, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  46. Association Between Clinical Tumor Burden and Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non–Small-Cell Lung Cancer

    Article • Clinical Lung Cancer, September 2020, Elsevier

    MD. PhD. Tateaki Naito

  47. Correction to: Clinical and radiation dose-volume factors related to pneumonitis after treatment with radiation and durvalumab in locally advanced non-small cell lung cancer

    Article • Investigational New Drugs, June 2020, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  48. Phase I trial of the MET inhibitor tepotinib in Japanese patients with solid tumors

    Article • Japanese Journal of Clinical Oncology, April 2020, Oxford University Press (OUP)

    MD. PhD. Tateaki Naito

  49. PD-L1 expression and response to pembrolizumab in patients with EGFR-mutant non-small cell lung cancer

    Article • Japanese Journal of Clinical Oncology, March 2020, Oxford University Press (OUP)

    MD. PhD. Tateaki Naito

  50. Clinical and radiation dose-volume factors related to pneumonitis after treatment with radiation and durvalumab in locally advanced non-small cell lung cancer

    Article • Investigational New Drugs, March 2020, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  51. Desensitizing effect of cachexia on immunotherapy in advanced lung cancer

    Article • JTO Clinical and Research Reports, March 2020, Elsevier

    MD. PhD. Tateaki Naito

  52. Evaluation of gefitinib systemic exposure in EGFR-mutated non-small cell lung cancer patients with gefitinib-induced severe hepatotoxicity

    Article • Cancer Chemotherapy and Pharmacology, February 2020, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  53. Development of the Early Nutritional Intervention for Elderly Patients with Advanced Cancer: Details of Nutritional Intervention in the Multimodal NEXTAC-ONE Program

    Article • Palliative Care Research, January 2020, Japanese Society for Palliative Medicine

    MD. PhD. Tateaki Naito

  54. Management of anorexia prevents skeletal muscle wasting during cisplatin‐based chemotherapy for thoracic malignancies

    Article • JCSM Clinical Reports, January 2020, Wiley

    MD. PhD. Tateaki Naito

  55. Characterization of tumour mutation burden in patients with non‐small cell lung cancer and interstitial lung disease

    Article • Respirology, November 2019, Wiley

    MD. PhD. Tateaki Naito

  56. Past, Now, and Future in Cancer Cachexia Research

    Article • Therapeutics and Clinical Risk Management, October 2019, Taylor & Francis

    MD. PhD. Tateaki Naito

  57. PD-L1 Expression and Response to Pembrolizumab in Japanese Patients with EGFR-Mutant Non-small Cell Lung Cancer

    Article • Annals of Oncology, October 2019, Elsevier

    MD. PhD. Tateaki Naito

  58. Anamorelin for Patients with Advanced Gastrointestinal Cancer and Cachexia

    Article • Cancer, August 2019, Wiley

    MD. PhD. Tateaki Naito

  59. Acquired immunodeficiency associated with thymoma: a case report

    Article • BMC Cancer, August 2019, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  60. Efficacy of daikenchuto, a traditional Japanese Kampo medicine, for postoperative intestinal dysfunction in patients with gastrointestinal cancers: meta-analysis

    Article • International Journal of Clinical Oncology, July 2019, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  61. Optimal Sequence of Local and EGFR-TKI Therapy for EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases Stratified by Number of Brain Metastases

    Article • International Journal of Radiation Oncology*Biology*Physics, July 2019, Elsevier

    MD. PhD. Tateaki Naito

  62. Negative impact of malignant effusion on osimertinib treatment for non-small cell lung cancer harboring EGFR mutation

    Article • Investigational New Drugs, June 2019, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  63. PROTOCOL: Randomized Phase II Trial of Multimodal NEXTAC program in Cancer Cachexia

    Article • BMC Cancer, May 2019, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  64. Changes in TROP2 expression in lung cancer patients receiving anticancer treatments.

    Article • Journal of Clinical Oncology, May 2019, American Society of Clinical Oncology (ASCO)

    MD. PhD. Tateaki Naito

  65. Impact of baseline number of metastases on the efficacy of PD-1 inhibitor monotherapy for non-small cell lung cancer with high PD-L1 expression.

    Article • Journal of Clinical Oncology, May 2019, American Society of Clinical Oncology (ASCO)

    MD. PhD. Tateaki Naito

  66. The impact of steroid use on efficacy of immunotherapy among patients with lung cancer who have developed immune-related adverse events.

    Article • Journal of Clinical Oncology, May 2019, American Society of Clinical Oncology (ASCO)

    MD. PhD. Tateaki Naito

  67. Foreign Body Impaction in the Esophagus

    Article • Mayo Clinic Proceedings, May 2019, Elsevier

    MD. PhD. Tateaki Naito

  68. Carboplatin Plus Nab-paclitaxel in Performance Status 2 Patients With Advanced Non-small-cell Lung Cancer

    Article • Anticancer Research, March 2019, International Institute of Anticancer Research

    MD. PhD. Tateaki Naito

  69. Genetic alterations of driver genes as independent prognostic factors for disease-free survival in patients with resected non-small cell lung cancer

    Article • Lung Cancer, February 2019, Elsevier

    MD. PhD. Tateaki Naito

  70. Nutritional Status is a Key in Treatment Decision in Cancer Patients with Poor Performance Status

    Article • Nutrition and Cancer, January 2019, Taylor & Francis

    Dr Akira Ono, MD. PhD. Tateaki Naito

  71. Palliative cerebrospinal fluid shunting for leptomeningeal metastasis-related hydrocephalus in patients with lung adenocarcinoma: A single-center retrospective study

    Article • PLoS ONE, January 2019, PLOS

    MD. PhD. Tateaki Naito

  72. What is the True Endpoint for Cancer Cachexia Care ?

    Article • Asia-Pacific Journal of Oncology Nursing, January 2019, Medknow

    MD. PhD. Tateaki Naito

  73. Efficacy of Second-line Chemotherapy in Patients With Sensitive Relapsed Small-cell Lung Cancer

    Article • In Vivo, January 2019, International Institute of Anticancer Research

    MD. PhD. Tateaki Naito

  74. New Combination of Exercise and Nutrition for Elderly Cancer Patients with Cachectic Risks

    Article • Journal of Cachexia Sarcopenia and Muscle, October 2018, Wiley

    MD. PhD. Tateaki Naito

  75. A multicenter, open-label, uncontrolled study of ONO-7643/anamorelin in cachexia patients with gastrointestinal cancer

    Article • Annals of Oncology, October 2018, Elsevier

    MD. PhD. Tateaki Naito

  76. Gefitinib-Induced Cardiomyopathy in Epidermal Growth Receptor-Mutated NSCLC

    Article • Journal of Thoracic Oncology, October 2018, Elsevier

    MD. PhD. Tateaki Naito

  77. A modified ILD-GAP index for patients with non-small cell lung cancer and interstitial lung disease

    Article • September 2018, European Respiratory Society (ERS)

    MD. PhD. Tateaki Naito

  78. Efficacy of second-line chemotherapy in poor-risk patients with refractory-relapsed small-cell lung cancer

    Article • Japanese Journal of Clinical Oncology, August 2018, Oxford University Press (OUP)

    MD. PhD. Tateaki Naito

  79. Isolation and molecular analysis of circulating tumor cells from lung cancer patients using a microfluidic chip type cell sorter

    Article • Cancer Science, July 2018, Wiley

    Dr. Hisao Imai, MD. PhD. Tateaki Naito

  80. Leptomeningeal recurrence after long-term alectinib therapy for non-small cell lung cancer harboring an EML4-ALK fusion protein

    Article • Investigational New Drugs, July 2018, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  81. ILD-NSCLC-GAP index scoring and staging system for patients with non-small cell lung cancer and interstitial lung disease

    Article • Lung Cancer, July 2018, Elsevier

    MD. PhD. Tateaki Naito

  82. Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments

    Article • International Journal of Clinical Oncology, June 2018, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  83. A Patient with a Massive Single Cardiac Metastasis of Lung Adenocarcinoma, Diagnosed via a Biopsy

    Article • Internal Medicine, June 2018, Japanese Society of Internal Medicine

    MD. PhD. Tateaki Naito

  84. Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials

    Article • British Journal of Cancer, May 2018, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  85. A randomized phase II study of the nutritional and exercise treatment for the elderly patients with advanced non-small cell lung or pancreatic cancer: The NEXTAC-TWO study.

    Article • Journal of Clinical Oncology, May 2018, American Society of Clinical Oncology (ASCO)

    MD. PhD. Tateaki Naito

  86. Optimal treatment sequence for untreated EGFR-mutant NSCLC with brain metastases.

    Article • Journal of Clinical Oncology, May 2018, American Society of Clinical Oncology (ASCO)

    MD. PhD. Tateaki Naito

  87. Crizotinib-induced simultaneous multiple cardiac toxicities

    Article • Investigational New Drugs, May 2018, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  88. Efficacy of prophylactic cranial irradiation in patients with limited-disease small-cell lung cancer who were confirmed to have no brain metastasis via magnetic resonance imaging after initial chemoradiotherapy

    Article • Oncotarget, April 2018, Impact Journals, LLC

    MD. PhD. Tateaki Naito

  89. Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR-Mutant Non–small-cell Lung Cancer

    Article • Clinical Lung Cancer, March 2018, Elsevier

    MD. PhD. Tateaki Naito

  90. Predictive role of CYFRA 21-1 in lung adenocarcinoma treated nivolumab therapy

    Article • Tumor Biology, February 2018, SAGE Publications

    Dr Akira Ono, MD. PhD. Tateaki Naito

  91. Hospitalization-associated Physical Inactivity and Cancer Cachexia

    Article • Asia-Pacific Journal of Oncology Nursing, January 2018, Medknow

    MD. PhD. Tateaki Naito

  92. Behavioral Change Technique is Key to Enrich QOL in Elderly Cancer Patients

    Article • Asia-Pacific Journal of Oncology Nursing, January 2018, Medknow

    MD. PhD. Tateaki Naito

  93. Development of Low-intensity Home-based Resistance Training for Elderly Patients with Advanced Cancer: The Exercise Component of the NEXTAC Program

    Article • Palliative Care Research, January 2018, Japanese Society for Palliative Medicine

    MD. PhD. Tateaki Naito

  94. Impact of Interstitial Lung Disease Classification on the Development of Acute Exacerbation of Interstitial Lung Disease and Prognosis in Patients with Stage III Non-Small-Cell Lung Cancer and Interstitial Lung Disease Treated With Chemoradiotherapy

    Article • Journal of Cancer, January 2018, Ivyspring International Publisher

    MD. PhD. Tateaki Naito

  95. Characteristics of cellular composition in malignant pericardial effusion and its association with the clinical course of carcinomatous pericarditis

    Article • Japanese Journal of Clinical Oncology, December 2017, Oxford University Press (OUP)

    MD. PhD. Tateaki Naito

  96. Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04)

    Article • Cancer, December 2017, Wiley

    JUNJI UCHINO, MD. PhD. Tateaki Naito

  97. Without Cachexia, We Could Live Longer and Die Shorter

    Article • BMC Cancer, November 2017, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  98. A Randomized Phase II Study Comparing Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutation–Positive Nonsquamous Non–Small-Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rati...

    Article • Clinical Lung Cancer, November 2017, Elsevier

    MD. PhD. Tateaki Naito

  99. Cardiac Dysfunction Caused by Osimertinib

    Article • Journal of Thoracic Oncology, October 2017, Elsevier

    MD. PhD. Tateaki Naito

  100. Progress in multimodal intervention for cancer cachexia

    Article • Annals of Oncology, October 2017, Elsevier

    MD. PhD. Tateaki Naito

  101. Comparison of Clinically Relevant Mutation Profiles Between Preoperative Biopsy and Corresponding Surgically Resected Specimens in Japanese Patients With Non–Small-cell Lung Cancer by Amplicon-based Massively Parallel Sequencing

    Article • Clinical Lung Cancer, September 2017, Elsevier

    MD. PhD. Tateaki Naito

  102. Negative Impact of Skeletal Muscle Wasting After Neoadjuvant Chemotherapy Followed by Surgery on Survival for Patients with Thoracic Esophageal Cancer

    Article • Annals of Surgical Oncology, August 2017, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  103. Losing Muscle during Chemotherapy Causes Physical Dysfunction in Elderly Lung Cancer Patients

    Article • BMC Cancer, August 2017, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  104. The effects of advanced age and serum α1 -acid glycoprotein on docetaxel unbound exposure and dose-limiting toxicity in cancer patients

    Article • British Journal of Clinical Pharmacology, August 2017, Wiley

    MD. PhD. Tateaki Naito

  105. Survival data for postoperative adjuvant chemotherapy comprising cisplatin plus vinorelbine after complete resection of non-small cell lung cancer

    Article • Cancer Chemotherapy and Pharmacology, July 2017, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  106. Negative impact of leukoaraiosis on the incidence of brain metastases in patients with lung cancer

    Article • Journal of Neuro-Oncology, July 2017, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  107. Tracheal granuloma 7 years after extubation

    Article • Respirology Case Reports, July 2017, Wiley

    MD. PhD. Tateaki Naito

  108. ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature

    Article • BMC Cancer, July 2017, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  109. A Phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy

    Article • Japanese Journal of Clinical Oncology, June 2017, Oxford University Press (OUP)

    MD. PhD. Tateaki Naito

  110. Modified GAP index for prediction of acute exacerbation of idiopathic pulmonary fibrosis in non-small cell lung cancer

    Article • Respirology, May 2017, Wiley

    MD. PhD. Tateaki Naito

  111. Long-term clinical outcomes of ALK inhibitors in patients with ALK-positive advanced non-small cell lung cancer.

    Article • Journal of Clinical Oncology, May 2017, American Society of Clinical Oncology (ASCO)

    MD. PhD. Tateaki Naito

  112. The incidence and risk factors of febrile neutropenia in chemotherapy-naïve lung cancer patients receiving etoposide plus platinum

    Article • Cancer Chemotherapy and Pharmacology, April 2017, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  113. Response to the treatment immediately before nivolumab monotherapy may predict clinical response to nivolumab in patients with non-small cell lung cancer

    Article • International Journal of Clinical Oncology, April 2017, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  114. Plasma epidermal growth factor receptor mutation testing with a chip-based digital PCR system in patients with advanced non-small cell lung cancer

    Article • Lung Cancer, April 2017, Elsevier

    MD. PhD. Tateaki Naito

  115. Amrubicin monotherapy may be an effective second-line treatment for patients with large-cell neuroendocrine carcinoma or high-grade non-small-cell neuroendocrine carcinoma

    Article • Molecular and Clinical Oncology, March 2017, Spandidos Publications

    MD. PhD. Tateaki Naito

  116. Osimertinib for pretreated epidermal growth factor receptor Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study

    Article • Translational Cancer Research, March 2017, AME Publishing Company

    MD. PhD. Tateaki Naito

  117. High incidence of interstitial lung disease following practical use of osimertinib in patients who had undergone immediate prior nivolumab therapy

    Article • Annals of Oncology, March 2017, Elsevier

    MD. PhD. Tateaki Naito

  118. Both Quantity and Quality of Skeletal Muscle are Important in Breast Cancer near the End of Life

    Article • Supportive Care in Cancer, February 2017, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  119. Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients

    Article • BMC Cancer, November 2016, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  120. Drastic initial response and subsequent response to two ALK inhibitors in a patient with a highly aggressive ALK-rearranged inflammatory myofibroblastic tumor arising in the pleural cavity

    Article • Lung Cancer, September 2016, Elsevier

    MD. PhD. Tateaki Naito

  121. Rebiopsy for patients with non‐small‐cell lung cancer after epidermal growth factor receptor‐tyrosine kinase inhibitor failure

    Article • Cancer Science, June 2016, Wiley

    MD. PhD. Tateaki Naito

  122. Dose escalation study of proton beam therapy with concurrent chemotherapy for stage III non‐small cell lung cancer

    Article • Cancer Science, June 2016, Wiley

    MD. PhD. Tateaki Naito

  123. Organizing Pneumonia Induced by Nivolumab in a Patient with Metastatic Melanoma

    Article • Journal of Thoracic Oncology, March 2016, Elsevier

    MD. PhD. Tateaki Naito

  124. Prognostic significance of diabetes mellitus in locally advanced non-small cell lung cancer

    Article • BMC Cancer, December 2015, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  125. Antihypertensive therapy of bevacizumab-induced hypertension

    Article • Annals of Oncology, November 2015, Elsevier

    MD. PhD. Tateaki Naito

  126. Comparison of platinum rechallenge and docetaxel in non-small cell lung cancer previously treated with chemoradiotherapy

    Article • Annals of Oncology, November 2015, Elsevier

    MD. PhD. Tateaki Naito

  127. The efficacy of amrubicin on central nervous system metastases originating from small-cell lung cancer: a case series of eight patients

    Article • Investigational New Drugs, April 2015, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  128. Comparison of platinum combination re-challenge therapy and docetaxel monotherapy in non-small cell lung cancer patients previously treated with platinum-based chemoradiotherapy

    Article • SpringerPlus, March 2015, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  129. Disease flare after gefitinib discontinuation

    Article • Respiratory Investigation, March 2015, Elsevier

    MD. PhD. Tateaki Naito

  130. Efficacy of Rechallenge Chemotherapy in Patients With Sensitive Relapsed Small Cell Lung Cancer

    Article • American Journal of Clinical Oncology, February 2015, Wolters Kluwer Health

    MD. PhD. Tateaki Naito

  131. Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease

    Article • Cancer Chemotherapy and Pharmacology, January 2015, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  132. Clinical impact of post-progression survival on overall survival in patients with limited-stage disease small cell lung cancer after first-line chemoradiotherapy

    Article • Radiology and Oncology, January 2015, De Gruyter

    Dr. Hisao Imai, MD. PhD. Tateaki Naito

  133. Primary malignant melanoma of the trachea: A case report

    Article • Oncology Letters, December 2014, Spandidos Publications

    MD. PhD. Tateaki Naito

  134. Phase II clinical trial of S-1 plus oral leucovorin in previously treated patients with non-small-cell lung cancer

    Article • Lung Cancer, December 2014, Elsevier

    MD. PhD. Tateaki Naito

  135. Cachexia Remains Prognostic throughout the Cancer Trajectry in NSCLC

    Article • Supportive Care in Cancer, November 2014, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  136. The effect of gefitinib in patients with postoperative recurrent non-small cell lung cancer harboring mutations of the epidermal growth factor receptor

    Article • International Journal of Clinical Oncology, October 2014, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  137. Identification of actionable mutations in malignant pleural mesothelioma

    Article • Lung Cancer, October 2014, Elsevier

    MD. PhD. Tateaki Naito

  138. Molecular Targeting Therapy and Csf Shunt for Patients with Leptomeningeal Metastasis From Lung Adenocarcinoma

    Article • Annals of Oncology, October 2014, Elsevier

    MD. PhD. Tateaki Naito

  139. Mutant allele frequency predicts the efficacy of EGFR-TKIs in lung adenocarcinoma harboring the L858R mutation

    Article • Annals of Oncology, October 2014, Elsevier

    MD. PhD. Tateaki Naito

  140. Multiplexed Molecular Profiling of Lung Cancer Using Pleural Effusion

    Article • Journal of Thoracic Oncology, July 2014, Elsevier

    MD. PhD. Tateaki Naito

  141. Individual-level data on the relationships of progression-free survival and post-progression survival with overall survival in patients with advanced non-squamous non-small cell lung cancer patients who received second-line chemotherapy

    Article • Medical Oncology, June 2014, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  142. Multimutational profiling of rebiopsy samples from NSCLC developing acquired resistance to EGFR-TKI in Japanese patients.

    Article • Journal of Clinical Oncology, May 2014, American Society of Clinical Oncology (ASCO)

    MD. PhD. Tateaki Naito

  143. Molecular profiling of small cell lung cancer in a Japanese cohort

    Article • Lung Cancer, May 2014, Elsevier

    MD. PhD. Tateaki Naito

  144. Toxicity and efficacy of chemotherapy for non-small cell lung cancer with cavitary lesions

    Article • Respiratory Investigation, May 2014, Elsevier

    MD. PhD. Tateaki Naito

  145. The Impact of Clinical Outcomes According to EGFR Mutation Status in Patients with Locally Advanced Lung Adenocarcinoma Who Recieved Concurrent Chemoradiotherapy

    Article • American Journal of Clinical Oncology, April 2014, Wolters Kluwer Health

    MD. PhD. Tateaki Naito

  146. Differences in the efficacy of S-1 monotherapy according to histological type in pretreated patients with advanced non-small cell lung cancer

    Article • Thoracic Cancer, March 2014, Wiley

    MD. PhD. Tateaki Naito

  147. Comparison of cisplatin plus pemetrexed and cisplatin plus gemcitabine for the treatment of malignant pleural mesothelioma in Japanese patients

    Article • Respiratory Investigation, March 2014, Elsevier

    MD. PhD. Tateaki Naito

  148. Prognostic impact of 18F-FDG uptake on PET in non-small cell lung cancer patients withpostoperative recurrence following platinum-based chemotherapy

    Article • Respiratory Investigation, March 2014, Elsevier

    MD. PhD. Tateaki Naito

  149. Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy

    Article • BMC Cancer, January 2014, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  150. Perianal Metastasis of Non-Small Cell Lung Cancer

    Article • Internal Medicine, January 2014, Japanese Society of Internal Medicine

    MD. PhD. Tateaki Naito

  151. Individual-level data on the relationships of progression-free survival, post-progression survival, and tumor response with overall survival in patients with advanced non-squamous non-small cell lung cancer

    Article • Neoplasma, January 2014, AEPress, s.r.o.

    MD. PhD. Tateaki Naito

  152. 18F-FDG uptake on PET is a predictive marker of thymidylate synthase expression in patients with thoracic neoplasms

    Article • Oncology Reports, October 2013, Spandidos Publications

    MD. PhD. Tateaki Naito

  153. Acute Lung Injury With Alveolar Hemorrhage As Adverse Drug Reaction Related to Crizotinib

    Article • Journal of Clinical Oncology, September 2013, American Society of Clinical Oncology (ASCO)

    MD. PhD. Tateaki Naito

  154. Outcome of platinum-based chemotherapy for non-small-cell lung cancer patients with pleural dissemination detected during surgery

    Article • Molecular and Clinical Oncology, August 2013, Spandidos Publications

    MD. PhD. Tateaki Naito

  155. Prognostic impact of serum CYFRA 21–1 in patients with advanced lung adenocarcinoma: a retrospective study

    Article • BMC Cancer, July 2013, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  156. Dose-Escalation Study of Three-Dimensional Conformal Thoracic Radiotherapy With Concurrent S-1 and Cisplatin for Inoperable Stage III Non–Small-Cell Lung Cancer

    Article • Clinical Lung Cancer, July 2013, Elsevier

    MD. PhD. Tateaki Naito

  157. Size-Based Isolation of Circulating Tumor Cells in Lung Cancer Patients Using a Microcavity Array System

    Article • PLoS ONE, June 2013, PLOS

    MD. PhD. Tateaki Naito

  158. Phase I study of highly selective inhibitor of VEGFR tyrosine kinase, tivozanib, in Japanese patients with solid tumors

    Article • Cancer Science, June 2013, Wiley

    MD. PhD. Tateaki Naito

  159. Microcavity Array System for Size-Based Enrichment of Circulating Tumor Cells from the Blood of Patients with Small-Cell Lung Cancer

    Article • Analytical Chemistry, June 2013, American Chemical Society (ACS)

    MD. PhD. Tateaki Naito

  160. The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors

    Article • Annals of Oncology, June 2013, Elsevier

    MD. PhD. Tateaki Naito

  161. Efficacy of bevacizumab-containing chemotherapy for non-squamous non-small cell lung cancer with bone metastases

    Article • Cancer Chemotherapy and Pharmacology, March 2013, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  162. Phase I and pharmacokinetic study of gefitinib and S-1 combination therapy for advanced adenocarcinoma of the lung

    Article • Cancer Chemotherapy and Pharmacology, January 2013, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  163. Papillary Squamous Cell Carcinoma of the Trachea Associated with Human Papillomavirus-18 Infection

    Article • Internal Medicine, January 2013, Japanese Society of Internal Medicine

    MD. PhD. Tateaki Naito

  164. Efficacy and Safety of Platinum Combination Chemotherapy Re-Challenge for Relapsed Patients with Non-Small-Cell Lung Cancer after Postoperative Adjuvant Chemotherapy of Cisplatin plus Vinorelbine

    Article • Chemotherapy, January 2013, Karger Publishers

    MD. PhD. Tateaki Naito

  165. Comparison of chemotherapeutic efficacy between LCNEC diagnosed using large specimens and possible LCNEC diagnosed using small biopsy specimens

    Article • International Journal of Clinical Oncology, December 2012, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  166. Chemoradiotherapy for Limited-disease Small-cell Lung Cancer in Elderly Patients Aged 75 Years or Older

    Article • Japanese Journal of Clinical Oncology, December 2012, Oxford University Press (OUP)

    MD. PhD. Tateaki Naito

  167. Feasibility of postoperative adjuvant chemotherapy of cisplatin plus vinorelbine for completely resected non-small-cell lung cancer: A retrospective study in Japan

    Article • Respiratory Investigation, December 2012, Elsevier

    MD. PhD. Tateaki Naito

  168. 260 Deformability-based Isolation of Circulating Tumor Cells in Lung Cancer Patients with Microcavity Array System

    Article • European Journal of Cancer, November 2012, Elsevier

    MD. PhD. Tateaki Naito

  169. 18F-FDG uptake on PET in primary mediastinal non-thymic neoplasm: A clinicopathological study

    Article • European Journal of Radiology, September 2012, Elsevier

    MD. PhD. Tateaki Naito

  170. Prognostic Impact of Serum Cyfra 21-1 In Advanced Lung Adenocarcinoma

    Article • Annals of Oncology, September 2012, Elsevier

    MD. PhD. Tateaki Naito

  171. Correlations between serial pro-gastrin-releasing peptide and neuron-specific enolase levels, and the radiological response to treatment and survival of patients with small-cell lung cancer

    Article • Lung Cancer, June 2012, Elsevier

    MD. PhD. Tateaki Naito

  172. Phase I Results of Vinorelbine With Concurrent Radiotherapy in Elderly Patients With Unresectable, Locally Advanced Non-Small-Cell Lung Cancer: West Japan Thoracic Oncology Group (WJTOG3005-DI)

    Article • International Journal of Radiation Oncology*Biology*Physics, April 2012, Elsevier

    MD. PhD. Tateaki Naito

  173. Prognostic Impact of Circulating Tumor Cells in Patients with Small Cell Lung Cancer

    Article • Journal of Thoracic Oncology, March 2012, Elsevier

    MD. PhD. Tateaki Naito

  174. The role of βIII-tubulin in non-small cell lung cancer patients treated by taxane-based chemotherapy

    Article • International Journal of Clinical Oncology, February 2012, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  175. Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors

    Article • Investigational New Drugs, January 2012, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  176. 18F-FDG uptake on PET could be a predictive marker of Excision Repair Cross-Complementation Group 1 (ERCC1) expression in patients with thoracic neoplasms?

    Article • Neoplasma, January 2012, AEPress, s.r.o.

    MD. PhD. Tateaki Naito

  177. Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure

    Article • Lung Cancer, December 2011, Elsevier

    MD. PhD. Tateaki Naito

  178. Expression of thymidylate synthase, orotate phosphoribosyltransferase and dihydropyrimidine dehydrogenase in thymic epithelial tumors

    Article • Lung Cancer, December 2011, Elsevier

    MD. PhD. Tateaki Naito

  179. Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4)

    Article • Cancer Chemotherapy and Pharmacology, November 2011, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  180. MUC1 Expression in Pulmonary Metastatic Tumors: A Comparison of Primary Lung Cancer

    Article • Pathology & Oncology Research, October 2011, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  181. Differential efficacy of docetaxel according to non-small cell lung cancer histology and the therapeutic effect of epidermal growth factor receptor tyrosine kinase inhibitors

    Article • Oncology Letters, August 2011, Spandidos Publications

    MD. PhD. Tateaki Naito

  182. Expression of 4F2hc (CD98) in pulmonary neuroendocrine tumors

    Article • Oncology Reports, July 2011, Spandidos Publications

    MD. PhD. Tateaki Naito

  183. The Risk of Cytotoxic Chemotherapy-Related Exacerbation of Interstitial Lung Disease with Lung Cancer

    Article • Journal of Thoracic Oncology, July 2011, Elsevier

    MD. PhD. Tateaki Naito

  184. RETRACTED ARTICLE: Relationship between 18F-FDG uptake on PET and various biologic molecular markers in benign pulmonary lesion: comparison with primary lung cancer

    Article • Annals of Nuclear Medicine, June 2011, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  185. Expression of Excision Repair Cross-Complementation Group 1, Breast Cancer Susceptibility 1, and β III-Tubulin in Thymic Epithelial Tumors

    Article • Journal of Thoracic Oncology, March 2011, Elsevier

    MD. PhD. Tateaki Naito

  186. Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: A pooled analysis of published reports

    Article • Cancer Science, February 2011, Wiley

    MD. PhD. Tateaki Naito

  187. Evaluation of the efficacy and safety of chemotherapy for patients with wet stage IIIB/IV non-small-cell lung cancer aged 80 years old or more

    Article • Lung Cancer, February 2011, Elsevier

    MD. PhD. Tateaki Naito

  188. Biologic correlates of 18F-FDG uptake on PET in pulmonary pleomorphic carcinoma

    Article • Lung Cancer, February 2011, Elsevier

    MD. PhD. Tateaki Naito

  189. Thenar muscle metastasis as recurrence of pulmonary squamous cell carcinoma

    Article • Asia-Pacific Journal of Clinical Oncology, January 2011, Wiley

    MD. PhD. Tateaki Naito

  190. 18F-FDG uptake on PET helps predict outcome and response after treatment in unresectable thymic epithelial tumors

    Article • Annals of Nuclear Medicine, December 2010, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  191. Intestinal metastasis from non-small-cell lung cancer initially detected by 18F-fluorodeoxyglucose positron emission tomography

    Article • Japanese Journal of Radiology, November 2010, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  192. Ratio of standardized uptake value on PET helps predict response and outcome after chemotherapy in advanced non-small cell lung cancer

    Article • Annals of Nuclear Medicine, September 2010, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  193. CD98 expression is associated with the grade of malignancy in thymic epithelial tumors

    Article • Oncology Reports, September 2010, Spandidos Publications

    MD. PhD. Tateaki Naito

  194. Biologic Correlation of 2-[18F]-Fluoro-2-Deoxy-D-Glucose Uptake on Positron Emission Tomography in Thymic Epithelial Tumors

    Article • Journal of Clinical Oncology, August 2010, American Society of Clinical Oncology (ASCO)

    MD. PhD. Tateaki Naito

  195. N-telopeptide of type I collagen is useful for monitoring therapeutic response in non-small cell lung cancer patients with bone metastases

    Article • International Journal of Clinical Oncology, June 2010, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  196. Comparison of chemotherapy for unresectable pulmonary high-grade non-small cell neuroendocrine carcinoma and small-cell lung cancer

    Article • Lung Cancer, June 2010, Elsevier

    MD. PhD. Tateaki Naito

  197. Erratum to: Evaluation of S-1 as third- or further-line chemotherapy in advanced non-small-cell lung cancer

    Article • International Journal of Clinical Oncology, April 2010, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  198. Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer

    Article • Lung Cancer, April 2010, Elsevier

    MD. PhD. Tateaki Naito

  199. Pulmonary Pleomorphic Carcinoma: A Clinicopathological Study Including EGFR Mutation Analysis

    Article • Journal of Thoracic Oncology, April 2010, Elsevier

    MD. PhD. Tateaki Naito

  200. Evaluation of S-1 as third- or further-line chemotherapy in advanced non-small-cell lung cancer

    Article • International Journal of Clinical Oncology, March 2010, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  201. Efficacy of chemotherapy with carboplatin and paclitaxel for unresectable thymic carcinoma

    Article • Lung Cancer, February 2010, Elsevier

    MD. PhD. Tateaki Naito

  202. Erratum to: Thymic squamous cell carcinoma producing granulocyte colony-stimulating factor associated with a high serum level of interleukin 6

    Article • International Journal of Clinical Oncology, January 2010, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  203. Long-term survivors of more than 5 years in advanced non-small cell lung cancer

    Article • Lung Cancer, January 2010, Elsevier

    MD. PhD. Tateaki Naito

  204. Thymic squamous cell carcinoma producing granulocyte colony-stimulating factor associated with a high serum level of interleukin 6

    Article • International Journal of Clinical Oncology, December 2009, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  205. Higher Sensitivity and Specificity for Diffusion-weighted Imaging of Malignant Lung Lesions without Apparent Diffusion Coefficient Quantification

    Article • Radiology, July 2009, Radiological Society of North America (RSNA)

    MD. PhD. Tateaki Naito

  206. Cumulative incidence of and predictive factors for lung cancer in IPF

    Article • Respirology, July 2009, Wiley

    MD. PhD. Tateaki Naito

  207. Acute exacerbation of interstitial pneumonia associated with collagen vascular diseases

    Article • Respiratory Medicine, June 2009, Elsevier

    MD. PhD. Tateaki Naito

  208. Evaluation of the Safety and Compliance of 3-Week Cycles of Vinorelbine on Days 1 and 8 and Cisplatin on Day 1 as Adjuvant Chemotherapy in Japanese Patients with Completely Resected Pathological Stage IB to IIIA Non-small Cell Lung Cancer: A Retrospect...

    Article • Japanese Journal of Clinical Oncology, December 2008, Oxford University Press (OUP)

    MD. PhD. Tateaki Naito

  209. S-1 Treatment for Chemorefractory Thymic Carcinoma

    Article • Journal of Thoracic Oncology, September 2008, Elsevier

    MD. PhD. Tateaki Naito

  210. Possible therapeutic effect of direct haemoperfusion with a polymyxin B immobilized fibre column (PMX‐DHP) on pulmonary oxygenation in acute exacerbations of interstitial pneumonia

    Article • Respirology, April 2008, Wiley

    MD. PhD. Tateaki Naito

  211. Lung Dendritic Cells Have a Potent Capability to Induce Production of Immunoglobulin A

    Article • American Journal of Respiratory Cell and Molecular Biology, February 2008, American Thoracic Society

    MD. PhD. Tateaki Naito

  212. Reactive Legionella pneumophila arthritis diagnosed by polymerase chain reaction

    Article • Rheumatology International, September 2006, Springer Science + Business Media

    MD. PhD. Tateaki Naito

  213. Lymphangitis Carcinomatosis as a Potential Predictor for a Response to Gefitinib

    Article • Clinical Oncology, September 2006, Elsevier

    MD. PhD. Tateaki Naito

  214. A Validation and Potential Modification of the Pneumonia Severity Index in Elderly Patients with Community-Acquired Pneumonia

    Article • Journal of the American Geriatrics Society, August 2006, Wiley

    MD. PhD. Tateaki Naito

  215. Interstitial lung diseases associated with amyopathic dermatomyositis

    Article • European Respiratory Journal, July 2006, European Respiratory Society (ERS)

    MD. PhD. Tateaki Naito

  216. Impaired Toll-like Receptor 9 Expression in Alveolar Macrophages with No Sensitivity to CpG DNA

    Article • American Journal of Respiratory and Critical Care Medicine, April 2005, American Thoracic Society

    MD. PhD. Tateaki Naito

  217. Efficacy of a consensus protocol therapy in adults with acute, severe asthma

    Article • Annals of Allergy Asthma & Immunology, March 2003, Elsevier

    MD. PhD. Tateaki Naito

  218. Well-differentiated Hepatocellular Carcinoma Showing Intrahepatic Neural Invastion: Autopsied Case

    Article • Japanese Journal of Clinical Oncology, April 1991, Oxford University Press (OUP)

    MD. PhD. Tateaki Naito